Publications

September 11, 2020

A Multi-Center, Open-Label Extension Study to Assess the Long-term Safety/Tolerability and Pharmacokinetics, and Explore the Efficacy of Sofpironium Bromide Gel, 15% Applied Topically to Children and Adolescents, 9 to 16 Years of Age, with Primary Axillary Hyperhidrosis
Poster Presentation at the Inaugural 2020 San Diego Dermatology Symposium

July 10, 2020

A Multi-Center, Open-Label Extension Study to Assess the Long-term Safety/Tolerability and Pharmacokinetics, and Explore the Efficacy of Sofpironium Bromide Gel, 15% Applied Topically to Children and Adolescents, 9 to 16 Years of Age, with Primary Axillary Hyperhidrosis
Poster Presentation at Society for Pediatric Dermatology 45th Annual Meeting

Hyperhidrosis Disease Severity Measure-Axillary (HDSM-AX): Evaluation of Measurement Properties in Phase II Study Data
Poster Presentation at Society for Pediatric Dermatology 45th Annual Meeting

June 25, 2020

A Multi-Center, Open-Label Extension Study to Assess the Long-term Safety/Tolerability and Pharmacokinetics, and Explore the Efficacy of Sofpironium Bromide Gel, 15% Applied Topically to Children and Adolescents, 9 to 16 Years of Age, with Primary Axillary Hyperhidrosis
Poster Presentation at Maui Derm Virtual Congress

Hyperhidrosis Disease Severity Measure-Axillary (HDSM-AX): Evaluation of Measurement Properties in Phase II Study Data
Poster Presentation at Maui Derm Virtual Congress

February 6, 2020

Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial
Journal of the American Academy of Dermatology

January 17, 2020

A Multi-Center, Open-Label Extension Study to Assess the Long-term Safety/Tolerability and Pharmacokinetics, and Explore the Efficacy of Sofpironium Bromide Gel, 15% Applied Topically to Children and Adolescents, 9 to 16 Years of Age, with Primary Axillary Hyperhidrosis
Poster Presentation at ODAC Dermatology, Aesthetic and Surgical Conference

October 17, 2019

A Multi-Center, Open-Label Study to Assess Pharmacokinetics (PK), Safety and Tolerability of Sofpironium Bromide Gel, 15% Applied Topically to Children and Adolescents, ≥9 to <17 Years of Age, with Axillary Hyperhidrosis
Poster Presentation at Fall Clinical Dermatology Conference